Germline or somatic BRCA1/2 mutations have been demonstrated to significantly affect tumour sensitivity to PARP inhibitors.39 The epigenetic silencing of BRCA1 represented 15% of sporadic ovarian cancers in a population‐based study. This evidence concerns the gene BRCA1 and ovarian carcinoma.